Jefferies Reiterates Buy on Integra LifeSciences (IART) After Meeting with Management

September 26, 2016 7:42 AM EDT
Get Alerts IART Hot Sheet
Price: $41.49 -1.19%

Rating Summary:
    15 Buy, 8 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 30 | Down: 30 | New: 23
Trade IART Now!
Join SI Premium – FREE

Get the Pulse of the Market with's Pulse Picks. Get your Free Trial here.

Jefferies reiterated a Buy rating and $95.00 price target on Integra LifeSciences (NASDAQ: IART) after visiting with management. Discussions were centered around the company's restructuring, as well as revenue performance and margin outlook. IART's recent growth has come from better execution in existing markets and the biggest new opportunities are still relatively untapped. The regenerative portfolio remains a highlight and management again stressed the combination of Omnigraft, the TEI products, and VolTAC antimicrobial dressing position as well positioned to make a run at the outpatient wound setting.

Analyst Raj Denhoy commented, "On Thursday, we visited IART in NJ. Several areas of discussion were the significant restructuring that has taken place at IART; the recent strong revenue performance; the outsized opportunities still teed up; and the outlook for margin improvement. While the level of near-term investment needed to realize the opportunities remains a question, the longer-term opportunity remains significant."

For an analyst ratings summary and ratings history on Integra LifeSciences click here. For more ratings news on Integra LifeSciences click here.

Shares of Integra LifeSciences closed at $86.87 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Jefferies & Co

Add Your Comment